Our findings demonstrate that the combination of RP116 reovirus and IL-18/-21-pretreated eNK cells exhibited promising additive anti-tumor effects against different grades of bladder cancer cell lines (5637, HT-1376, and 253J-BV). This evidence concerns the gene IL18 and urinary bladder cancer.